中文名称 | (2S,3R,4R,5S,6R)-2-(4-氯-3-(4-乙氧基苄基)苯基)-6-(羟甲基)四氢-2H-吡喃-3,4,5-三醇 |
---|---|
英文名称 | Dapagliflozin (BMS-512148; 达格列净) |
CAS号 | 461432-26-8 |
分子式 | C21H25ClO6 |
分子量 | 408.87 |
MDL | MFCD13182359 |
外观 | White to off-white powder |
储存条件 | Dry, dark and at 0 - 4 ℃ for short term (days to weeks) or -20 ℃ for long term (months to years). |
Dapagliflozin (formerly known as BMS-512148; trade names Farxiga in the US and Forxiga in the EU) is a potent and selective hSGLT2 (sodium-glucose transport proteins) inhibitor with anti-diabetic activity. It inhibits hSGLT2 with an EC50 of 1.1 nM, and exhibits1200-fold selectivity over hSGLT1. Dapagliflozin inhibits subtype 2 of the sodium-glucose transport proteins (SGLT2) which are responsible for at least 90% of the glucose reabsorption in the kidney. Urine is the means by which blood glucose is expelled when this transporter mechanism is blocked.
© 2020-2024 凯立德生物医药技术(上海)有限公司 版权所有
沪ICP备15046197号-3
沪公网安备31011502007856号
Designed by Kuanersoft